Abstract 699P
Background
According to phase III FLAURA-2 study, first-line(1L) osimertinib(osi) plus chemotherapy significantly improves progression free survival compared to osi monotherapy in advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) patients(pts). Here, we conducted a real-world analysis to further validate the clinical efficacy and safety of osi plus chemotherapy as 1L in advanced EGFRm NSCLC pts in real-world setting.
Methods
Pts with metastatic EGFRm NSCLC who received osi plus chemotherapy as 1L treatment between Jan 1st, 2017 to Dec 31th, 2023 at Shanghai Chest Hospital were identified. Data of clinicopathological characteristics of these pts was collected. The real-world progression free survival (rwPFS), objective response rate (ORR), disease control rate (DCR) and safety profile were evaluated and analyzed.
Results
A total of 62 pts were included in this analysis, with 31 males (50%), and a median age of 58 years. Among them, all pts were stage IV, 44 pts (71.0%) were never smoker, 59 pts (92.5%) were ECOG PS of 0-1, 52 pts (83.9%) had adenocarcinoma, and 31 pts (50.0%) had brain metastasis (BM). Both 19del and L858R comprised 23 pts (37.1%), while rest of pts had other EGFR mutations. In terms of chemotherapy regimens combined with osi in 1L setting, 48 pts (77.1%) received platinum plus pemetrexed, 5 patients (8.1%) received pemetrexed monotherapy, while the rest of pts received other chemotherapy regimens. At median follow-up of 29.5 months, the median rwPFS for the overall population was 28.0 months. The median rwPFS of 28.3 months in pts with 19del, and 34.0 months in pts with L858R. In pts with CNS metastases, the median rwPFS was 28.0 months. Among 46 pts with assessable response, the ORR was 65.2% in the overall population, with 76.5% in pts with 19del and 72.2% in pts with L858R, respectively. The disease control rate was 95.7%. The safety profile of these pts was consistent with previously reported data.
Conclusions
Osi combined with chemotherapy as 1L treatment in metastatic EGFR-mutant NSCLC pts in real-world setting has demonstrated comparable effectiveness and manageable safety profile with previous data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.